What the research found

Researchers tested FLO23011, a treatment combining glucose with beta-hydroxybutyrate, against standard glucose gel in 12 people with type 1 diabetes over two 6-week periods. Participants rated their experience across 14 domains—covering things like speed of symptom relief, lingering side effects, and ease of use—while wearing continuous glucose monitors.

FLO23011 scored higher across nearly all measures. Users reported it worked faster, produced fewer after-effects (like the "rebound" feeling after treating a low), and was simpler to use. Qualitative interviews highlighted faster mental clarity recovery and reduced disruption to daily life. The data also suggested two potential patterns: people who experienced fewer severe lows with FLO23011 reported less worry and felt more in control; separately, those with higher baseline glucose variability saw larger improvements in time-in-range when using FLO23011.

Why it matters for you

If you manage type 1 diabetes and track continuous glucose data, the subjective experience of hypoglycemia recovery probably matters as much as the numbers. Lows disrupt sleep, work, and training; they also drive anxiety that can persist even after glucose normalizes. This work suggests that how you feel recovering matters—and that different glucose profiles might respond better to different treatments.

The finding about baseline variability is worth noting if you're someone with erratic glucose patterns. High variability suggests your system might benefit disproportionately from a dual-substrate approach, translating to better overall time-in-range. Conversely, if your variability is already low and controlled, the relative gain might be smaller.

One practical takeaway: if you're considering hypoglycemia treatments, pay attention to post-recovery experience, not just speed to 100 mg/dL. Mental fog, jitteriness, or the "crash" afterward all affect quality of life and may differ between options.

Caveats

• Very small sample (n=12); results are exploratory and correlation-based, not causal
• Open-label design (both participants and researchers knew which treatment was used), introducing bias in subjective ratings
• Associations between CGM metrics and outcomes are based on tiny subgroups (n=5 and n=9) and need validation
• No blinded control group; comparison is against one alternative, not against a neutral benchmark
• Early-stage findings; authors themselves call for larger, blinded confirmation studies before clinical recommendations